» Articles » PMID: 31555350

MicroRNA-135a-5p is Involved in Osteoporosis Progression Through Regulation of Osteogenic Differentiation by Targeting RUNX2

Overview
Journal Exp Ther Med
Specialty Pathology
Date 2019 Sep 27
PMID 31555350
Citations 12
Authors
Affiliations
Soon will be listed here.
Abstract

A number of microRNAs (miRs) have been revealed to be involved in the development of osteoporosis, including postmenopausal osteoporosis. The aim of the present study was to investigate miR-135a-5p expression and the cellular function of miR-135a-5p and its underlying mechanism in postmenopausal osteoporosis. miR-135a-5p expression levels in the femoral neck trabecular bone tissue fragments from postmenopausal women with or without osteoporosis were detected by reverse transcription-quantitative polymerase chain reaction and western blot analysis. The role of miR-135a-5p during osteogenic differentiation was examined by performing gain- and loss-of-function experiments using miR-135a-5p mimic or inhibitor. TargetScan bioinformatics analysis was sued to predict targets of miR-135a-5p, which were confirmed using luciferase reporter assays. miR-135a-5p expression was significantly upregulated in femoral neck trabecular bone tissue fragments from postmenopausal women with osteoporosis compared with postmenopausal women without osteoporosis. In addition, miR-135a-5p expression levels significantly decreased during osteogenic differentiation in the C2C12 cell model. miR-135a-5p overexpression decreased the osteogenic potential of C2C12 cells, as miR-135a-5p overexpression significantly reduced the expression levels of several key osteoblast markers, whilst miR-135a-5p knockdown had the opposite effect. Furthermore, the current study demonstrated that RUNX2 was a direct target of miR-135a-5p. Rescue experiments indicated that RUNX2 overexpression significantly reversed the effect of miR-135a-5p mimic on the osteogenic potential of C2C12 cells, indicating that miR-135a-5p mediates osteogenic differentiation via direct targeting of RUNX2. Taken together, these results suggest that miR-135a-5p may serve a role in osteoporosis progression by regulating osteogenic differentiation via RUNX2.

Citing Articles

Supragingival Bacterium Oral Infection-Induced Periodontitis and Robust miRNA Expression Kinetics.

Aravindraja C, Jeepipalli S, Duncan W, Vekariya K, Rahaman S, Chan E Int J Mol Sci. 2024; 25(11).

PMID: 38892405 PMC: 11172800. DOI: 10.3390/ijms25116217.


Common miRNAs of Osteoporosis and Fibromyalgia: A Review.

Philippe S, Delay M, Macian N, Morel V, Pickering M Int J Mol Sci. 2023; 24(17).

PMID: 37686318 PMC: 10488272. DOI: 10.3390/ijms241713513.


Runx2 and Nell-1 in dental follicle progenitor cells regulate bone remodeling and tooth eruption.

Zeng L, He H, Sun M, Gong X, Zhou M, Hong Y Stem Cell Res Ther. 2022; 13(1):486.

PMID: 36175952 PMC: 9524038. DOI: 10.1186/s13287-022-03140-3.


Osteoporosis pathogenesis and treatment: existing and emerging avenues.

Liang B, Burley G, Lin S, Shi Y Cell Mol Biol Lett. 2022; 27(1):72.

PMID: 36058940 PMC: 9441049. DOI: 10.1186/s11658-022-00371-3.


Identification of circRNA Expression Profiles in BMSCs from Glucocorticoid-Induced Osteoporosis Model.

Chen Z, Lin W, Zhao S, Mo X, Wen Z, Cheung W Stem Cells Int. 2022; 2022:3249737.

PMID: 35154330 PMC: 8837445. DOI: 10.1155/2022/3249737.


References
1.
Shin C, Lecanda F, Sheikh S, Weitzmann L, Cheng S, Civitelli R . Relative abundance of different cadherins defines differentiation of mesenchymal precursors into osteogenic, myogenic, or adipogenic pathways. J Cell Biochem. 2000; 78(4):566-77. View

2.
Livak K, Schmittgen T . Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2002; 25(4):402-8. DOI: 10.1006/meth.2001.1262. View

3.
Chen D, Zhao M, Mundy G . Bone morphogenetic proteins. Growth Factors. 2004; 22(4):233-41. DOI: 10.1080/08977190412331279890. View

4.
Raisz L . Pathogenesis of osteoporosis: concepts, conflicts, and prospects. J Clin Invest. 2005; 115(12):3318-25. PMC: 1297264. DOI: 10.1172/JCI27071. View

5.
Soifer H, Rossi J, Saetrom P . MicroRNAs in disease and potential therapeutic applications. Mol Ther. 2007; 15(12):2070-9. DOI: 10.1038/sj.mt.6300311. View